|
1
|
Linehan WM, Srinivasan R and Schmidt LS:
The genetic basis of kidney cancer: A metabolic disease. Nat Rev
Urol. 7:277–285. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Znaor A, Lortet-Tieulent J, Laversanne M,
Jemal A and Bray F: International variations and trends in renal
cell carcinoma incidence and mortality. Eur Urol. 67:519–530. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ljungberg B, Bensalah K, Canfield S,
Dabestani S, Hofmann F, Hora M, Kuczyk MA, Lam T, Marconi L and
Merseburger AS: EAU guidelines on renal cell carcinoma: 2014
update. Eur Urol. 67:913–924. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Moch H, Cubilla AL, Humphrey PA, Reuter VE
and Ulbright TM: The 2016 WHO classification of tumours of the
urinary system and male genital organs-part A: Renal, penile, and
testicular tumours. Eur Urol. 70:93–105. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Signoretti S, Chen YB, Reuter VE and
Flaifel A: Renal cell carcinoma in the era of precision medicine:
From molecular pathology to tissue-based biomarkers. J Clin Oncol.
36:3553–3559. 2018. View Article : Google Scholar
|
|
6
|
Shalabi A, Abassi Z, Awad H, Halachmi S,
Moskovitz B, Kluger Y and Nativ O: Urinary NGAL and KIM-1:
Potential association with histopathologic features in patients
with renal cell carcinoma. World J Urol. 31:1541–1545. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kjeldsen LS, Johnsen AH, Sengeløv H and
Borregaard N: Isolation and primary structure of NGAL, a novel
protein associated with human neutrophil gelatinase. J Biol Chem.
268:10425–10432. 1993.PubMed/NCBI
|
|
8
|
Castillo-Rodriguez E, Fernandez-Prado R,
Martin-Cleary C, Pizarro-Sánchez MS, Sanchez-Niño MD, Sanz AB,
Fernandez-Fernandez B and Ortiz A: Kidney injury marker 1 and
neutrophil gelatinase-associated lipocalin in chronic kidney
disease. Nephron. 136:263–267. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Makris K, Rizos D, Kafkas N and Haliassos
A: Neurophil gelatinase-associated lipocalin as a new biomarker in
laboratory medicine. Clin Chem Lab Med. 50:1519–1532. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roli L, Pecoraro V and Trenti T: Can NGAL
be employed as prognostic and diagnostic biomarker in human
cancers? A systematic review of current evidence. Int J Biol
Markers. 32:e53–e61. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lippi G, Meschi T, Nouvenne A, Mattiuzzi C
and Borghi L: Neutrophil gelatinase-associated lipocalin in cancer.
Adv Clin Chem. 64:179–219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Monisha J, Roy NK, Padmavathi G, Banik K,
Bordoloi D, Khwairakpam AD, Arfuso F, Chinnathambi A, Alahmadi TA,
Alharbi SA, et al: NGAL is downregulated in oral squamous cell
carcinoma and leads to increased survival, proliferation, migration
and chemoresistance. Cancers (Basel). 10:2282018. View Article : Google Scholar
|
|
13
|
Barresi V, Ieni A, Bolignano D, Magno C,
Buemi M and Barresi G: Neutrophil gelatinase-associated lipocalin
immunoexpression in renal tumors: Correlation with histotype and
histological grade. Oncol Rep. 24:305–310. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marti J and Fuster J: Prognostic value of
serum neutrophil gelatinase-associated lipocalin in metastatic and
non-metastatic colorectal cancer: Reply. World J Surg. 37:27292013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu B, Jin DY, Lou WH and Wang DS:
Lipocalin-2 is associated with a good prognosis and reversing
epithelial-to-mesenchymal transition in pancreatic cancer. World J
Surg. 37:1892–1900. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bundgaard JR, Sengeløv H, Borregaard N and
Kjeldsen L: Molecular cloning and expression of a cDNA encoding
NGAL: A lipocalin expressed in human neutrophils. Biochem Biophys
Res Commun. 202:1468–1475. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Cowland JB and Borregaard N: Molecular
characterization and pattern of tissue expression of the gene for
neutrophil gelatinase-associated lipocalin from humans. Genomics.
45:17–23. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chakraborty S, Kaur S, Guha S and Batra
SK: The multifaceted roles of neutrophil gelatinase associated
lipocalin (NGAL) in inflammation and cancer. Biochim Biophys Acta.
1826:129–169. 2012.PubMed/NCBI
|
|
19
|
Vaidya VS, Ferguson MA and Bonventre JV:
Biomarkers of acute kidney injury. Ann Rev Pharmacol Toxicol.
48:463–493. 2008. View Article : Google Scholar
|
|
20
|
Friedl A, Stoesz SP, Buckley P and Gould
MN: Neutrophil gelatinase-associated lipocalin in normal and
neoplastic human tissues. Cell type-specific pattern of expression.
Histochem J. 31:433–441. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lippi G and Plebani M: Neutrophil
gelatinase-associated lipocalin (NGAL): The laboratory perspective.
Clin Chem Lab Med. 0:1–5. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zabron AA, Horneffer-van der Sluis VM,
Wadsworth CA, Laird F, Gierula M, Thillainayagam AV, Vlavianos P,
Westaby D, Taylor-Robinson SD, Edwards RJ and Khan SA: Elevated
levels of neutrophil gelatinase-associated lipocalin in bile from
patients with malignant pancreatobiliary disease. Am J
Gastroenterol. 106:1711–1717. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Capoluongo E, Vento G, Lulli P, Di Stasio
E, Porzio S, Vendettuoli V, Tana M, Tirone C, Romagnoli C, Zuppi C
and Ameglio F: Epithelial lining fluid
neutrophil-gelatinase-associated lipocalin levels in premature
newborns with bronchopulmonary dysplasia and patency of ductus
arteriosus. Int J Immunopathol Pharmacol. 21:173–179. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kotyza J, Bunatova K, Pesek M and Puzman
P: Pleural injury and pleurisy-induced progelatinase B/proMMP-9 is
associated with markers of neutrophil degranulation. Scand J Clin
Lab Invest. 66:487–496. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lippi G, Caleffi A, Pipitone S, Elia G,
Ngah A, Aloe R, Avanzini P and Ferrari C: Assessment of neutrophil
gelatinase-associated lipocalin and lactate dehydrogenase in
peritoneal fluids for the screening of bacterial peritonitis. Clin
Chim Acta. 418:59–62. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lippi G, Avanzini P, Calzetti C, Caleffi
A, Pipitone S, Musa R, Aloe R and Ferrari C: The role of neutrophil
gelatinase-associated lipocalin (NGAL) in cerebrospinal fluids for
screening of acute bacterial meningitis. Clin Lab. 60:377–381.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Schmidt-Otta KM, Mori K, Kalandadzea A, Li
JY, Paragasa N, Nicholas T, Devarajan P and Barasch J: Neutrophil
gelatinase-associated lipocalin-mediated iron traffic in kidney
epithelia. Curr Opin Nephrol Hypertens. 15:442–449. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soni SS, Cruz D, Bobek I, Chionh CY,
Nalesso F, Lentini P, de Cal M, Corradi V, Virzi G and Ronco C:
NGAL: A biomarker of acute kidney injury and other systemic
conditions. Int Urol Nephrol. 42:141–150. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gwira JA, Wei F, Ishibe S, Ueland JM,
Barasch J and Cantley LG: Expression of neutrophil
gelatinase-associated lipocalin regulates epithelial morphogenesis
in vitro. J Biol Chem. 280:7875–7882. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goetz DH, Willie ST, Armen RS, Bratt T,
Borregaard N and Strong RK: Ligand preference inferred from the
structure of neutrophil gelatinase associated lipocalin.
Biochemistry. 39:1935–1941. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yan L, Borregaard N, Kjeldsen L and Moses
MA: The high molecular weight urinary matrix metalloproteinase
(MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil
gelatinase-associated lipocalin (NGAL). Modulation of MMP-9
activity by NGAL. J Biol Chem. 276:37258–37265. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Antonucci E, Lippi G, Ticinesi A, Pigna F,
Guida L, Morelli I, Nouvenne A, Borghi L and Meschi T: Neutrophil
gelatinase-associated lipocalin (NGAL): A promising biomarker for
the early diagnosis of acute kidney injury (AKI). Acta Biomed.
85:289–294. 2014.PubMed/NCBI
|
|
33
|
Rosner MH: Urinary biomarkers for the
detection of renal injury. Adv Clin Chem. 49:73–97. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Cervellin G and di Somma S: Neutrophil
gelatinase-associated lipocalin (NGAL): The clinician's
perspective. Clin Chem Lab Med. 50:1489–1493. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kjeldsen L, Cowland JB and Borregaard N:
Human neutrophil gelatinase-associated lipocalin and homologous
proteins in rat and mouse. Biochim Biophys Acta. 1482:272–283.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Garay-Rojas E, Harper M, Hraba-Renevey S
and Kress M: An apparent autocrine mechanism amplifies the
dexamethasone- and retinoic acid-induced expression of mouse
lipocalin-encoding gene 24p3. Gene. 170:173–180. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Wenners AS, Mehta K, Loibl S, Park H,
Mueller B, Arnold N, Hamann S, Weimer J, Ataseven B, Darb-Esfahani
S, et al: Neutrophil gelatinase-associated lipocalin (NGAL)
predicts response to neoadjuvant chemotherapy and clinical outcome
in primary human breast cancer. PLoS One. 7:e458262012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhang M, Zhao X, Deng Y, Tang B, Sun Q,
Zhang Q, Chen W, Yao D, Yang J, Cao L and Guo H: Neutrophil
gelatinase associated lipocalin is an independent predictor of poor
prognosis in cases of papillary renal cell carcinoma. J Urol.
194:647–652. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Perrin C, Patard JJ, Jouan F, Collet N,
Théoleyre S, Edeline J, Zerrouki S, Laguerre B, Bellaud-Roturaud
MA, Rioux-Leclercq N and Vigneau C: The neutrophil
gelatinase-associated lipocalin, or LCN 2, marker of aggressiveness
in clear cell renal cell carcinoma. Prog Urol. 21:851–858. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Liu F, Li N, Yang W, Wang R, Yu J and Wang
X: The expression analysis of NGAL and NGALR in clear cell renal
cell carcinoma. Gene. 676:269–278. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Rehwald C, Schnetz M, Urbschat A, Mertens
C, Meier JK, Bauer R, Baer P, Winslow S, Roos FC and Zwicker K: The
iron load of lipocalin-2 (LCN-2) defines its pro-tumour function in
clear-cell renal cell carcinoma. Br J Cancer. 122:421–433. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Barresi V, Reggiani-Bonetti L, Di Gregorio
C, Vitarelli E, De Leon MP and Barresi G: Neutrophil
gelatinase-associated lipocalin (NGAL) and matrix
metalloproteinase-9 (MMP-9) prognostic value in stage I colorectal
carcinoma. Pathol Res Pract. 207:479–486. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Lang H, Lindner V, de Fromont M, Molinié
V, Letourneux H, Meyer N, Martin M and Jacqmin D: Multicenter
determination of optimal interobserver agreement using the fuhrman
grading system for renal cell carcinoma: Assessment of 241 patients
with > 15-year follow-up. Cancer. 103:625–629. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Haase-Fielitz A, Haase M and Devarajan P:
Neutrophil gelatinase-associated lipocalin as a biomarker of acute
kidney injury: A critical evaluation of current status. Ann Clin
Biochem. 51:335–351. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Devarajan P: Neutrophil
gelatinase-associated lipocalin (NGAL): A new marker of kidney
disease. Scand J Clin Lab Invest Suppl. 241:89–94. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Candido S, Abrams SL, Steelman LS,
Lertpiriyapong K, Fitzgerald TL, Martelli AM, Cocco L, Montalto G,
Cervello M, Polesel J, et al: Roles of NGAL and MMP-9 in the tumor
microenvironment and sensitivity to targeted therapy. Biochim
Biophys Acta. 1863:438–448. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Morrissey JJ, London AN, Lambert MC and
Kharasch ED: Sensitivity and specificity of urinary neutrophil
gelatinase-associated lipocalin and kidney injury molecule-1 for
the diagnosis of renal cell carcinoma. Am J Nephrol. 34:391–398.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
DI Carlo A: Evaluation of neutrophil
gelatinase-associated lipocalin (NGAL), matrix metalloproteinase-9
(MMP-9) and their complex MMP-9/NGAL in sera and urine of patients
with kidney tumors. Oncol Lett. 5:1677–1681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Saint F, Rose-Robert F, Herpe YE, de Sousa
P, Sevestre H, Choukhroun G and Amant C: ARCHITECT®
urine-neutrophil gelatinase-associated lipocalin (uNGAL) essay: New
prognostic marker for clear cell renal cell carcinoma (ccRCC).
Annals Oncol. 28:vii92017. View Article : Google Scholar
|
|
50
|
Porta C, Paglino C, De Amici M, Quaglini
S, Sacchi L, Imarisio I and Canipari C: Predictive value of
baseline serum vascular endothelial growth factor and neutrophil
gelatinase-associated lipocalin in advanced kidney cancer patients
receiving sunitinib. Kidney Int. 77:809–815. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yu DS, Wu CL, Ping SY, Huang YL and Shen
KH: NGAL can alternately mediate sunitinib resistance in renal cell
carcinoma. J Urol. 192:559–566. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Bolignano D, Donato V, Lacquaniti A, Fazio
MR, Bono C, Coppolino G and Buemi M: Neutrophil
gelatinase-associated lipocalin (NGAL) in human neoplasias: A new
protein enters the scene. Cancer Lett. 288:10–16. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang XF, Zhang Y, Zhang XH, Zhou SM, Yang
GG, Wang OC, Guo GL, Yang GY and Hu XQ: Clinical significance of
neutrophil gelatinase-associated lipocalin(NGAL) expression in
primary rectal cancer. BMC Cancer. 9:1342009. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Bouchet S and Bauvois B: Neutrophil
gelatinase-associated lipocalin (NGAL), pro-matrix
metalloproteinase-9 (pro-MMP-9) and their complex pro-MMP-9/NGAL in
leukaemias. Cancers (Basel). 6:796–812. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Monier F, Surla A, Guillot M and Morel F:
Gelatinase isoforms in urine from bladder cancer patients. Clin
Chim Acta. 299:11–23. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hawinkels LJ, Zuidwijk K, Verspaget HW, de
Jonge-Muller ES, van Duijn W, Ferreira V, Fontijn RD, David G,
Hommes DW, Lamers CB and Sier CF: VEGF release by MMP-9 mediated
heparan sulphate cleavage induces colorectal cancer angiogenesis.
Eur J Cancer. 44:1904–1913. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Van den Steen PE, Van Aelst I, Hvidberg V,
Piccard H, Fiten P, Jacobsen C, Moestrup SK, Fry S, Royle L,
Wormald MR, et al: The hemopexin and O-glycosylated domains tune
gelatinase B/MMP-9 bioavailability via inhibition and binding to
cargo receptors. J Biol Chem. 281:18626–18637. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Torti SV and Torti FM: Iron and cancer:
More ore to be mined. Nat Rev Cancer. 13:342–355. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Mertens C, Mora J, Ören B, Grein S,
Winslow S, Scholich K, Weigert A, Malmström P, Forsare C, Fernö M,
et al: Macrophage-derived lipocalin-2 transports iron in the tumor
microenvironment. Oncoimmunology. 7:e14087512018. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Yoshiji H, Harris SR and Thorgeirsson UP:
Thorgeirsson: Vascular endothelial growth factor is essential for
initial but not continued in vivo growth of human breast carcinoma
cells. Cancer Res. 57:3924–3928. 1997.PubMed/NCBI
|
|
61
|
Ferreira AC, Da Mesquita S, Sousa JC,
Correia-Neves M, Sousa N, Palha JA and Marques F: From the
periphery to the brain: Lipocalin-2, a friend or foe? Prog
Neurobiol. 131:120–136. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Yang J, Bielenberg DR, Rodig SJ, Doiron R,
Clifton MC, Kung AL, Strong RK, Zurakowski D and Moses MA:
Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci
USA. 106:3913–3918. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Iannetti A, Pacifico F, Acquaviva R,
Lavorgna A, Crescenzi E, Vascotto C, Tell G, Salzano AM, Scaloni A,
Vuttariello E, et al: The neutrophil gelatinase-associated
lipocalin (NGAL), a NF-kappaB-regulated gene, is a survival factor
for thyroid neoplastic cells. Proc Natl Acad Sci USA.
105:14058–14063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Tong Z, Kunnumakkara AB, Wang H, Matsuo Y,
Diagaradjane P, Harikumar KB, Ramachandran V, Sung B, Chakraborty
A, Bresalier RS, et al: Neutrophil gelatinase-associated lipocalin:
A novel suppressor of invasion and angiogenesis in pancreatic
cancer. Cancer Res. 68:6100–6108. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Le NT and Richardson DR: The role of iron
in cell cycle progression and the proliferation of neoplastic
cells. Biochim Biophys Acta. 1603:31–46. 2002.PubMed/NCBI
|
